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Abstract
Introduction: Breast cancer is the most common malignancy affecting females worldwide but conventional risk factors are
able to explain only a small proportion of these cases. A possible viral etiology for breast cancer has been proposed and
Epstein-Barr Virus (EBV) is a widely researched candidate virus. The aim of the present study, first one of its kind from India,
was to determine if there is a greater association of EBV infection with breast cancer patients as compared to patients with
benign breast diseases.
Methods: We looked for expression of Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) in breast cancer tissue specimens by
employing immunohistochemistry (IHC). We also measured levels of anti-EBNA-1 Immunoglobulin (IgG) antibodies in stored
sera of these patients using commercial Enzyme linked Immunosorbent Assay (ELISA) kit. Patients with benign breast
diseases were used as a comparison group for both immunohistochemical and serological analysis.
Results: 58 cases of malignant breast disease and 63 of benign breast disease (controls) were included in the study. Using
manufacturer determined cut-off of 3 IU/ml, 50/55 tested (90.9%) cases and 27/33 tested (81.8%) controls were seropositive
for anti-EBNA-1 IgG. Mean antibody levels were significantly higher for cases (54.22 IU/ml) as compared to controls
(18.68 IU/ml). IHC for EBNA-1 was positive in 28/51 cases (54.9%). No IHC positivity was noted in the tested 30 controls. Our
results show that EBNA-1 expression is seen in a significant proportion of breast cancer tissue specimens from rural India
and as compared to patients with benign breast diseases these patients also have a higher immunological response against
EBNA-1.
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Introduction
Breast cancer is the most common malignancy affecting women
world-wide with an annual incidence of around 800,000
cases.[1,2] Though various reproductive and hormonal factors
have been identified as risk factors for breast cancer, but even
together these factors do not explain more than fifty percent of all
cases of breast cancer.[1,3] This prompted the researchers to look
for other risk factors including a possible viral etiology for breast
cancer. Mouse mammary tumor virus (MMTV) has been
implicated in causing mammary carcinoma in mice but search
for similar viral sequences in humans have not yielded conclusive
results.[4] Since then many other candidate viruses like Epstein-
Barr Virus (EBV) and Human Papilloma Virus (HPV) have been
proposed.[5,6]
A possible association of EBV with breast cancer was thought of
because of the following observations: High incidence of male
breast cancers has been reported in Mediterranean countries
which are endemic for EBV, some EBV associated lymphomas are
known to occur in breast and there are morphological similarities
between medullary carcinoma of breast and nasopharngeal
carcinoma (NPC), an EBV associated malignancy.[4] EBV has
also been found in breast tissue and milk, lymphoblastoid cell lines
bearing EBV can infect mammary epithelial cells in vitro and
transfection of p31 fragment of EBV DNA immortalizes epithelial
cells including mammary epithelial cells.[5] If a causal association
of EBV with breast cancer is established, it would have therapeutic
significance because of the possible role of EBV specific cytotoxic
T cells in targeting EBV associated tumor cells.[7]
Most of the studies detecting association of carcinoma breast
with EBV infection have been carried out in western countries, but
in-order to establish causation consistent results have to be
demonstrated from studies conducted all over the world [8,9] as
EBV infection is prevalent worldwide. So far only few such studies
have been reported from Asian countries and none from India.
The aim of the current study was to determine if there is a greater
association of EBV infection in female breast cancer patients from
rural India as compared to those with a benign breast disease. For
investigating this association we performed immunohistochemistry
(IHC) for Epstein Barr Virus Nuclear Antigen-1 (EBNA-1) in
breast tissue specimens, and also looked for presence of antibodies
to EBNA-1 in serum samples of patients with benign and
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8180malignant breast diseases. Of the various known antigens of EBV
expression, EBNA-1is essential for maintenance of viral episome
and is expressed in all known forms of viral latency. [10] To the
best of our knowledge this is the first study in which both serology
and IHC for presence of viral protein has been done on the same
study subjects.
Methods
Ethics Statement
This study was approved by the Mahatma Gandhi Institute of
Medical Sciences (MGIMS), Institutional review board for
research in human subjects located at Sevagram, India (Registered
with United States Department of Health and Human services,
registration #IRB00003623). Patients who were at least 18 years
of age, did not have a relative with breast cancer were approached
for participation in the study. Those who provided a written
informed consent were included.
Setting
This prospective case-control study was conducted at MGIMS,
Sevagram, a rural based teaching hospital in central India, to
determine the association between EBV infection and breast
cancer. MGIMS is part of a nation-wide cancer registry, and in
2001–04 about one-fifth of all malignancies in women were breast
neoplasms. Breast cancer is second only to cervical cancer in rural
population based cancer registry in India, with age adjusted rate of
breast cancer estimated to be about 9.7 per 100,000 popula-
tion.[11]
Cases and Controls
All consecutive women who underwent surgical excision for
diagnosis or treatment of their breast lumps were considered for
inclusion in this study. A study investigator approached the
patients in the surgical ward, within 48 hrs of excision biopsy or
mastectomy. Patients were informed about the subsequent study
procedures and informed consent was sought. Patients who were
at least 18 years of age, did not have a relative with breast cancer
and provided written informed consent were included in the study.
A detailed clinical and reproductive history was obtained from all
such patients, a serum sample was collected and all serum samples
were stored at 270 degree centigrade at this time.
The breast tissues from these patients were received in the
histopathology services, grossed and subjected to tissue processing.
Based on histopathological examination, the included patients
were classified as cases if there was presence of invasive breast
cancer or carcinoma-in-situ. Women whose breast lesions had
either of the following diagnoses: Fibroadenosis, Duct ectasia,
Fibroadenoma, Fibrosis, Mastitis, or mild hyperplasia without
atypia, ordinary cysts (gross or microscopic), simple apocrine
metaplasia (no associated hyperplasia or adenosis), or squamous
metaplasia were classified as controls. Patients with lesions such as
sclerosing adenosis, fibraoadenoma with complex features, mod-
erate or florid hyperplasia without atypia, or atypical ductal or
lobular hyperplasia were excluded from being either a case or a
control. All histopathological slides were re-analysed independent-
ly by two trained pathologists and a consensus diagnosis was
obtained. In cases of malignancy, size of the tumor, histological
type of the tumor, grade of the tumor, and presence of metastatic
lymphnodes were also noted.
Immunohistochemistry(IHC)
We used paraffin embedded sections taken on amino-propyl-
triethoxysilane coated slides for IHC. Tissue was fixed in 10%
formalin. All paraffin blocks were stored at room temperature
before further processing. The paraffin sections were deparaffi-
nized and pretreated in 10 Mm citrate buffer (ph 6) in microwave
oven for 20 minutes. Endogenous peroxidase activity was blocked
by 3% hydrogen peroxide. After washing with phosphate buffered
saline, slides were treated with power block reagent (BioGenex,
San Ramon, CA, USA) and then with primary monoclonal
antibody clone 0211 (AbD Serotec, Raliegh, NC, USA) at a
dilution of 1:10 for one hour. Bound antibody was detected using
polymer horse radish peroxidase(HRP) conjugated anti-rabbit and
anti- mouse antibody. (BioGenex, San Ramon, CA, USA).
Peroxidase activity was detected by using 3,39 diaminobenzidine
(DAB) as chromogen with hydrogen peroxide as substrate.
Sections were then counterstained by hematoxylin. Known case
of NPC was taken as positive control, addition of monoclonal
antibody was omitted in negative control. All IHC tests were
performed by the same trained laboratory personnel.
Serology
ELISA for IgG antibodies against EBNA-1 was performed on
serum samples of cases and controls using a commercial ELISA kit
(Serion Immunodiagnostics, Wurzburg, Germany). The test was
carried out using manufacturer’s instructions. Briefly, 100 mLo f
standard diluted sera was pipetted into microtest wells and
incubated for 60 minutes at 37uC. After subsequent washing,
conjugate solution was added and incubated for 30 minutes at
37uC. After washing steps, addition of substrate solution and a
second incubation (30 minutes at 37uC), reaction was stopped and
extinction values were read at 405 nm. Continuous determination
of antibody activity was done by using the provided standard
curve. The test kit has inbuilt positive and negative controls, and
their values need to be in specified range for quality control to be
met. The assay run in this study met the quality control. The kit
cannot reliably measure IgG antibody levels above 110 IU/mL,
hence all high values are truncated at this point. Due to limited
resources we performed serology in cases and half of randomly
selected controls. Serology assay for all samples was performed by
one supervised laboratory technician in a single sitting.
Statistical Analysis
We performed a descriptive statistical analysis about distribution
of key demographic, reproductive, IHC and serologic features
between cases and controls. In addition we also compared tumor
grade, and stage between those who were positive or negative for
EBNA-1 expression on IHC. The difference between continuous
and discrete variables was compared using student’s t-test and chi
square tests respectively and p,0.01 was used to classify difference
between two groups as significant. We also compared the level of
anti- EBNA-1 antibodies in serum samples between cases and
controls as a continuous measure. All statistical analysis was done
using statistical software STATA version 9.0.
Results
The study included a total of 131 patients who presented
between January 2007 and March 2008. Of these patients a total
of 121 were finally included in the study, 58 patients were classified
as cases (malignant breast disease), and remaining 63 as
controls.(Figure 1). The mean age of cases was 47.2 (S.D 10.2)
years, and was significantly higher as compared to that of controls
27.5 (S.D 12.0) years (p,0.01). Due to this age difference, cases
were also more likely to be married, had more pregnancies and as
compared to controls, a higher proportion of women had lactated
in the past. (Table 1)
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33/63 (54.3%) controls. Using manufacturer determined cut-off
of 3 IU/ml, 50/55 (90.9%) cases and 27/33 (81.8%) controls
were seropositive for anti-EBNA-1 IgG. Mean anti-EBNA-1 IgG
levels were significantly higher for cases as compared to controls,
54.22 IU/ml (SD 46.70) (Median 34, range 0 to 110) versus
18.68 IU/ml (SD 14.80) (Median 16, range 0 to 50). We also
analyzed serology results stratified by age. None of the women
aged less than 25 years had malignant breast disease. Only three
women above the age of 45 years had a benign breast disease. In
Figure 1. Study flow.
doi:10.1371/journal.pone.0008180.g001
Table 1. Baseline characteristics between those with benign and malignant lesions.
Variable Benign (n=63) Malignant (n=58) P value
Age (years) 27.53 (12) 47.22 (10.2) ,0.01
Duration of lump (months) 14.86(18.8) 8.2 (9.5) 0.01
Respiratory infection past 6 months* 7 (11.1%) 5 (8.6%) 0.64
Age of menarche (years) 13.79 (1.98) 13.87 (1.18) 0.77
Years since marriage 10.95 (10.14) 18.20 (4.45) ,0.01
One or more conception (number) 29 57
Age (years) at first conception{ 20.58 (2.95) 20.56 (3.70) 0.97
Number of pregnancies{ 2.33 (0.96) 3.08 (1.56) 0.02
Number of children{ 2.22 (0.93) 2.80 (1.34) 0.04
Ever lactated* 28 (44.4%) 53 (91.3%) ,0.01
Oral contraceptive use* 4 (6.35%) 1 (1.72%) 0.202
Hormonal agents used * 2 (3.2%) 2 (3.4%) 0.93
EBNA-1 IgG serology done (number) 33 55 –
EBNA-1 IgG levels (IU/ml) Mean 18.68 (14.80) 54.22 (46.70) ,0.01
EBNA-1 IgG levels (IU/ml) Median 16 34
EBNA-1 IgG levels (IU/ml) Range 0–50 0–110
IHC for EBNA-1 done 30 51 ,0.01
Positive (%) 0 (0) 28 (54.9)
All values indicate mean (standard deviation) unless stated otherwise.
*Number (percentage).
{In those with one or more conceptions.
doi:10.1371/journal.pone.0008180.t001
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had malignant breast disease. The 16 of the 30 women in this
age group who had a benign breast disease and in whom
serology was performed, mean IgG levels (17.37 IU/mL; SD
16.89) were significantly lower as compared to those with
malignant breast disease (48.15; SD 47.38 IU/ml) (p=0.01)
(figure 2).
Of the 51 cases in whom IHC for EBNA-1 was performed, 28
were positive (54.9%). In the positive slides, about 3 to 50% of the
tumor cells showed intense nuclear granularity. No positivity was
noted in the infiltrating lymphocytes, surrounding stroma or
adjacent non-cancerous tissue (figure 3). All tested 30 controls were
negative for EBNA-1 expression by IHC. Of 48 cases in whom
both serology and IHC were performed, 25 (52.1%) were
concordant positive, 2 (4.6%) concordant negative, while remain-
ing 21 (43.5%) were positive by one of the two tests. Among 30
controls where both tests were done, none was concordant
positive, 6 (20%) were concordant negative, while 24 (80%) were
positive by serology alone. Among 51 cases in whom IHC was
done, EBNA-1 positivity was not found to be associated with age,
clinical or reproductive characteristics or tumor aggressiveness.
(Table 2)
Discussion
In the current study we found that about 55% of breast cancer
cases showed EBNA-1 expression in tumor cells by IHC, while all
the controls with benign breast disease were negative. On the
other hand although both cases as well as controls had a high sero-
prevalence of EBV infection (proportion positive for EBNA-1 IgG
antibodies 90.90% and 81.8% respectively), but IgG levels were
significantly higher in cases as compared to controls. These
findings suggest that EBV infection may have a role in causing
breast cancer.
Our results support the findings of some studies where
expression of EBNA-1 has been noted in cases of breast cancer.
(Table 3) Few of these studies also showed presence of EBV
DNA on polymerase chain reaction (PCR).[10,12,13] Like
other studies we also observed focal positivity in breast cancer
cases. No positivity in cases of benign breast diseases has also
been reported by Preciado etal [12], Roberio-Silva etal [14]
and Fawzy etal. [13]. Grinstein etal [15] and Roberio-Silva
etal [14] have observed nuclear positivity for EBNA-1 in
atypical breast hyperplasias and carcinoma in situ. Some
investigators have reported that EBV expression is more
commonly seen in tumors of higher grade,[10,16] no such
association between tumor grade and EBNA-1 expression was
noted in our study. Only two patients with malignant breast
disease in our study had a low grade malignancy (tumor grade
I), and all remaining had high tumor grades (II, and III). Thus
a lack of contrast in disease severity in our study population is a
likely explanation for why our results were different from
previous reports.
Figure 2. Box plot showing anti-EBNA-1 IgG antibody levels in women with benign and malignant breast disease, stratified by age.
The central horizontal line in the box indicates the median value, edges of the box indicate inter-quartile range, and the whiskers indicate values at
5
th and 95
th percentiles. The values at the bottom of the box indicate the number of women in whom serology was done, out of the total number of
eligible women in particular category. The mean IgG levels in 25 to 45 year age group were significantly higher in women with malignant breast
disease (48.15; SD 47.38 IU/ml) as compared to those with benign breast disease (17.37; SD 16.89 IU/mL) (p=0.01).
doi:10.1371/journal.pone.0008180.g002
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of infection in breast cancer patients. [17,18]. Traditional marker
of EBV infection was investigated in only one study and the
authors measured EBV IgG levels in stored plasma of 208 breast
cancer patients and169 controls. Similar seroprevalence of EBV
infection was noted in cases and controls (97 and 96 percent
respectively), but in contrast to the present study, mean IgG levels
were not found to be higher in cases as compared to controls (2.65
vs 2.57).[18]
The mean age of cases and controls (47.22 and 27.52 years
respectively) in our study is significantly different, hence the
serological findings need to be interpreted with caution. It could be
argued that since cases belong to an older age group, increased
antibody levels against EBNA-1 are simply because of multiple re-
infections which occur over a period of time. However, our age
stratified analysis shows that even in 25 to 45 years of age category,
the IgG levels in women with malignant breast disease were
significantly higher. Yasui et al [19] hypothesized that delayed
primary EBV infection is associated with a heightened immune
response and an elevated risk of breast cancer. Though in this
study we cannot ascertain the timing of infection in cases, but in
comparison to controls they definitely had a heightened immune
response against EBNA-1.
There were 18 cases which were negative for EBNA-1
expression on IHC but had positive serology results and 3 cases
which were positive for EBNA-1 on IHC but negative on serology.
The reason for results of these latter three cases is not exactly clear.
The most likely reason could be technical. We have used stored
sera and hemolysis, lipemia or contaminated sera could result into
false positive or false negative results. It is also known that most but
not all individuals form anti-EBNA-1 antibodies after EBV
infection and in some cases these antibodies disappear secondarily
and thus do not persist lifelong. Such cases should be investigated
for presence of viral capsid antigen antibodies before labelling
them as seronegative.[20]
Many investigators have questioned the role of EBV as a primary
etiologic agent for breast cancer. Major reasons for this controversy
have been firstly, the inconsistency of results in different studies
and secondly, detection of EBV expression in only a subset of tumor
cells. Initial studies focused primarily on association of medullary
carcinoma with EBV infection, and yielded negative results.[21,22].
Subsequently, Laberque et al [23] raised the possibility of
association of invasive ductal and lobular carcinoma with EBV
infection, but the results from various follow-up studies have yielded
variable results.[7,10,12,13,14,15,16,24,25,26,27,28,29,30,31,32,
33,34,35,36,37,38,39,40,41,42,43] Part of this variability can be
Figure 3. Immunohistochemical detection of EBNA-1 in breast tissue specimens. A. Tumor cells (infiltrating ductal carcinoma) showing
intense granular nuclear positivity for EBNA-1 antibody. B. Benign breast tissue negative for EBNA-1; C. Positive control (nasopharyngeal carcinoma
tumor cells showing nuclear positivity for EBNA-1) slide; D. Negative control (no signal is seen in infiltrating ductal carcinoma cells without application
of primary antibody). All photographs and in 400x original magnification.
doi:10.1371/journal.pone.0008180.g003
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three techniques have been used to determine EBV expression in
breast cancer cells IHC (EBNA-1, EBNA-2, LMP), In-situ
hybridization (ISH) for EBV encoded nuclear RNA (EBER), and
PCR for EBV-DNA. IHCfor EBNA-1 has yielded higher positivity,
however concerns remain regarding the specificity of the antibody
used in some of these studies.[34,44] The studies which have used
EBNA-1 as a target antigen are summarized in table 3. Studies
which have used LMP-1 and EBNA-2 have mostly yielded negative
results. This can be explained by the fact that these antigens are
differentially expressed in EBV associated malignancies.[5] ISH
targeting EBER is considered as a gold standard for detecting latent
EBV infection. However the results of the studies detecting EBER
by ISH in breast cancer specimens have been mostly negative. This
discrepancy may be due to non-expression of EBER in breast
cancer.[5] Conventional PCR based studies have been unable to
differentiate between EBV-DNA of tumor cells from EBV-DNA of
circulating lymphocytes. Use of Laser micro-dissection to separate
out tumor cells alone, followed by PCR testing can potentially solve
this limitation, yet the results based on these studies have been
contradictory. [16,28,33,34]
Secondly, the reason for only some of the tumor cells being
positive for EBV expression could be because of low expression of
protein in tumor cells or because of poor accessibility of the
antibody to the antigenic site. Even in NPC, which is known to be
caused by EBV infection, not all tumor cells are stained by the
antibody.[10] Another possible reason of variable IHC staining
could be that EBV is a hit and run virus, and after transformation
of breast epithelial cells, it gets lost from tumor cells [5,10] Arbach
et al [40] demonstrated that EBV genome is heterogeneously
distributed amongst morphologically indistinguishable tumor cells
which could account for the variable expression of EBNA-1 in
tumor cells. They also suggested that infection with EBV at a late
stage of tumor development may enhance it’s oncogenic properties
like invasion, angiogenesis and metastasis. They demonstrated that
in vitro infection of breast carcinoma cells by EBV confers
paclitaxel resistance and evokes overexpression of a multi drug
resistance gene so even if a small population of breast carcinoma
cells are infected by EBV, the impact of EBV infection on efficacy
of anticancer treatment would be of importance.[40]
Table 2. Demographic, reproductive and tumor severity amongst cases (n=51) with positive or negative IHC.
IHC EBNA-1 positive
N=28 (55%)
IHC EBNA-1 negative
N=23 (46%) P value
Age (years) 45.5 (8.7) 47.0 (10.4) 0.62
Duration (months) 7.3 (9.3) 7.6 (9.5) 0.91
Age of menarche (years) 14 (1.4) 13.7 (0.76) 0.32
Pregnancies (no)* 2.82 (1.49) 3.04 (1.82) 0.63
Number of children* 2.64 (1.47) 2.73 (1.28) 0.80
Never lactated* 3 (10.7%) 2 (8.7%) 0.81
Tumor grade *
I
II
III
1 (3.6%)
12 (42.8%)
15 (53.5%)
1 (4.5%)
8 (36.3%)
13 (59.1%)
0.89
Tumor size*
T1
T2
T3
T4
0 (0%)
11 (39.3%)
13 (46.4%)
4 (14.3%)
2 (8.7%)
8 (34.7%)
10 (43.5%)
3 (13.0%)
0.46
Lymph-node involvement*
N0
N1
N2
N3
8 (28.6%)
7 (25.0%)
8 (28.6%)
5 (17.9%)
8 (34.7%)
8 (34.7%)
5 (21.7%)
2 (8.7%)
0.66
Distant metastasis*
M0
M1
26 (92.8%)
2 (7.1%)
22 (95.6%)
1 (4.3%)
0.67
All values indicate mean (standard deviation) unless stated otherwise.
*Number (percentage).
doi:10.1371/journal.pone.0008180.t002
Table 3. Previous published studies which evaluated EBNA-1
by IHC on breast cancer specimens.
First author, year
EBNA-1 positive/
Total
% of cells
stained
Bonnet[10] 1999 9/9* 5–30
Brink[27] 2000 1/5* NA
Chu[31]2001 12/48 ,1
Grinstein[15] 2002 14/33 5–30
Deshpande [32]2002 0/43 0
Hermann [7]2003 0/59 0
Roberio-Silva[14] 2004 29/73 NA
Preciado [12] 2005 24/69 5–60
Shereen Fawzy[13] 2008 10/40 5–60
*IHC was done on EBV-DNA PCR positive samples only.
doi:10.1371/journal.pone.0008180.t003
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looking for evidence of association of EBV infection with breast
cancer which has been conducted in India. In India breast cancer
occurs at a younger age, and traditional reproductive risk factors
are uncommon. In this setting looking for novel etiological factors
becomes important. Secondly, we looked for evidence of EBV
infection in both serum as well as breast tissue specimens in
prospectively collected samples. Thirdly, we employed an in-situ
technique to demonstrate viral protein in breast tissue. Lastly, we
demonstrated expression of EBNA1, a protein essential for
maintaining viral episome. Presence of this protein helps to
establish EBV infection in tumor cells.
This study also has certain limitations. Firstly our sample size is
small and the results cannot be generalized to normal population.
Secondly we have not been able to find age matched controls for
each case as in general the mean age of controls is lower than that
of cases. This is a major limitation in statistical comparison of
antibody levels between the two groups. Thirdly we have looked
for expression of only one viral protein: EBNA-1, ideally we should
have investigated for multiple proteins present in different forms of
viral latency seen in other EBV associated tumors. Also we have
investigated for presence of EBNA-1 expression in tissues only by
IHC and that too by using only one monoclonal antibody. In-
order to prove specificity of the antibody we have used, we need to
reproduce our results by using another monoclonal antibody
against EBNA-1.
Molecular evidence of association is also required to substan-
tiate our results.
Our results show that expression of EBNA-1 is seen in a large
subset of breast cancer cases and a high immunological response to
EBNA-1 is also seen in these patients. Considering the magnitude
of breast cancer, role of EBV in either causation or progression of
breast cancer even in a small subset of breast cancer would be of
paramount importance. Further research is warranted to define
the exact role of EBV in the etiology or progression of breast
cancer as it would help in designing preventive, early detection
and treatment strategies.
Acknowledgments
Authors thank Mr Dilip Zade (BSc), Rekha Zade (MSc), and VM Patil
(BSc) for technical support during the study.
Author Contributions
Conceived and designed the experiments: DJ NG. Performed the
experiments: DJ MQ NG NG. Analyzed the data: DJ MQ NG RJ NG.
Contributed reagents/materials/analysis tools: DJ MQ NG. Wrote the
paper: DJ RJ NG.
References
1. Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk – where do
we stand in 2005? J Cell Mol Med 9: 208–221.
2. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast
cancer-epidemiology, risk factors, and genetics. Bmj 321: 624–628.
3. (2001) Familial breast cancer: collaborative reanalysis of individual data from 52
epidemiological studies including 58,209 women with breast cancer and 101,986
women without the disease. Lancet 358: 1389–1399.
4. Mant C, Hodgson S, Hobday R, D’Arrigo C, Cason J (2004) A viral aetiology
for breast cancer: time to re-examine the postulate. Intervirology 47: 2–13.
5. Glaser SL, Hsu JL, Gulley ML (2004) Epstein-Barr virus and breast cancer: state
of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev 13:
688–697.
6. Band V, Zajchowski D, Kulesa V, Sager R (1990) Human papilloma virus
DNAs immortalize normal human mammary epithelial cells and reduce their
growth factor requirements. Proc Natl Acad Sci U S A 87: 463–467.
7. Herrmann K, Niedobitek G (2003) Lack of evidence for an association of
Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res 5:
R13–17.
8. Hill AB (1965) The Environment and Disease: Association or Causation?
Proc R Soc Med 58: 295–300.
9. Susser M (1991) What is a cause and how do we know one? A grammar for
pragmatic epidemiology American journal of epidemiology 133: 635–648.
10. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, et al.
(1999) Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer
Inst 91: 1376–1381.
11. Nandkumar A (2001) National Cancer Registry Program. Bangalore: Indian
Council of Medical Research.
12. Preciado MV, Chabay PA, De Matteo EN, Gonzalez P, Grinstein S, et al. (2005)
Epstein-Barr virus in breast carcinoma in Argentina. Arch Pathol Lab Med 129:
377–381.
13. Fawzy S, Sallam M, Awad NM (2008) Detection of Epstein-Barr virus in breast
carcinoma in Egyptian women. Clin Biochem 41: 486–492.
14. Ribeiro-Silva A, Ramalho LN, Garcia SB, Zucoloto S (2004) Does the
correlation between EBNA-1 and p63 expression in breast carcinomas provide a
clue to tumorigenesis in Epstein-Barr virus-related breast malignancies?
Braz J Med Biol Res 37: 89–95.
15. Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren WH, et al. (2002)
Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res
62: 4876–4878.
16. Fina F, Romain S, Ouafik L, Palmari J, Ben Ayed F, et al. (2001) Frequency and
genome load of Epstein-Barr virus in 509 breast cancers from different
geographical areas. Br J Cancer 84: 783–790.
17. Angeloni A, Farina A, Gentile G, Capobianchi A, Martino P, et al. (2001)
Epstein-Barr virus and breast cancer: search for antibodies to the novel BFRF1
protein in sera of breast cancer patients. J Natl Cancer Inst 93: 560–561.
18. Richardson AK, Cox B, McCredie MR, Dite GS, Chang JH, et al. (2004)
Cytomegalovirus, Epstein-Barr virus and risk of breast cancer before age 40
years: a case-control study. Br J Cancer 90: 2149–2152.
19. Yasui Y, Potter JD, Stanford JL, Rossing MA, Winget MD, et al. (2001) Breast
cancer risk and ‘‘delayed’’ primary Epstein-Barr virus infection. Cancer
Epidemiol Biomarkers Prev 10: 9–16.
20. Hess RD (2004) Routine Epstein-Barr virus diagnostics from the laboratory
perspective: still challenging after 35 years. J Clin Microbiol 42: 3381–3387.
21. Gaffey MJ, Frierson HF Jr, Mills SE, Boyd JC, Zarbo RJ, et al. (1993) Medullary
carcinoma of the breast. Identification of lymphocyte subpopulations and their
significance. Mod Pathol 6: 721–728.
22. Lespagnard L, Cochaux P, Larsimont D, Degeyter M, Velu T, et al. (1995)
Absence of Epstein-Barr virus in medullary carcinoma of the breast as
demonstrated by immunophenotyping, in situ hybridization and polymerase
chain reaction. Am J Clin Pathol 103: 449–452.
23. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE (1995) Epstein-Barr virus
in epithelial cell tumors: a breast cancer study. Cancer Res 55: 39–45.
24. Luqmani YA, Shousha S (1995) Presence of Epstein-Barr virus in breast
carcinoma. Int J Oncol 6: 899–903.
25. Chu JS, Chen CC, Chang KJ (1998) In situ detection of Epstein-Barr virus in
breast cancer. Cancer Lett 124: 53–57.
26. Glaser SL, Ambinder RF, DiGiuseppe JA, Horn-Ross PL, Hsu JL (1998)
Absence of Epstein-Barr virus EBER-1 transcripts in an epidemiologically
diverse group of breast cancers. Int J Cancer 75: 555–558.
27. Brink AA, van Den Brule AJ, van Diest P, Meijer CJ (2000) Re: detection of
Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 92: 655–656;
author reply 656.
28. McCall SA, Lichy JH, Bijwaard KE, Aguilera NS, Chu WS, et al. (2001)
Epstein-Barr virus detection in ductal carcinoma of the breast. J Natl Cancer
Inst 93: 148–150.
29. Dadmanesh F, Peterse JL, Sapino A, Fonelli A, Eusebi V (2001) Lymphoe-
pithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus
infection. Histopathology 38: 54–61.
30. Kijima Y, Hokita S, Takao S, Baba M, Natsugoe S, et al. (2001) Epstein-Barr
virus involvement is mainly restricted to lymphoepithelial type of gastric
carcinoma among various epithelial neoplasms. J Med Virol 64: 513–518.
31. Chu PG, Chang KL, Chen YY, Chen WG, Weiss LM (2001) No significant
association of Epstein-Barr virus infection with invasive breast carcinoma.
Am J Pathol 159: 571–578.
32. Deshpande CG, Badve S, Kidwai N, Longnecker R (2002) Lack of expression of
the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and
LMP2A, in breast cancer cells. Lab Invest 82: 1193–1199.
33. Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE (2003) Epstein-Barr
virus gene expression in human breast cancer: protagonist or passenger?
Br J Cancer 89: 113–119.
34. Murray PG, Lissauer D, Junying J, Davies G, Moore S, et al. (2003) Reactivity
with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1
defines a subset of aggressive breast cancers in the absence of the EBV genome.
Cancer Res 63: 2338–2343.
35. Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD (2003) Lytic
viral replication as a contributor to the detection of Epstein-Barr virus in breast
cancer. J Virol 77: 13267–13274.
EBV and Breast Cancer
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e818036. Perrigoue JG, den Boon JA, Friedl A, Newton MA, Ahlquist P, et al. (2005) Lack
of association between EBV and breast carcinoma. Cancer Epidemiol
Biomarkers Prev 14: 809–814.
37. Horiuchi K, Mishima K, Ohsawa M, Aozasa K (1994) Carcinoma of stomach
and breast with lymphoid stroma: localisation of Epstein-Barr virus. J Clin
Pathol 47: 538–540.
38. Thorne LB, Ryan JL, Elmore SH, Glaser SL, Gulley ML (2005) Real-time PCR
measures Epstein-Barr Virus DNA in archival breast adenocarcinomas. Diagn
Mol Pathol 14: 29–33.
39. Tsai JH, Tsai CH, Cheng MH, Lin SJ, Xu FL, et al. (2005) Association of viral
factors with non-familial breast cancer in Taiwan by comparison with non-
cancerous, fibroadenoma, and thyroid tumor tissues. J Med Virol 75: 276–281.
40. Arbach H, Viglasky V, Lefeu F, Guinebretiere JM, Ramirez V, et al. (2006)
Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of
EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol
80: 845–853.
41. Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, et al. (2006)
Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer
primary biopsy specimens by real time PCR. Breast Cancer Research 8: R70.
42. Trabelsi A, Rammeh S, Stita W, Mokni M, Mourou A, et al. (2008) [Detection
of Epstein-Barr virus in breast cancers with lymphoid stroma]. Ann Biol Clin
(Paris) 66: 59–62.
43. Kalkan A, Ozdarendeli A, Bulut Y, Yekeler H, Cobanoglu B, et al. (2005)
Investigation of Epstein-Barr virus DNA in formalin-fixed and paraffin-
embedded breast cancer tissues. Med Princ Pract 14: 268–271.
44. Hennard C, Pfuhl T, Buettner M, Becker KF, Knofel T, et al. (2006) The
antibody 2B4 directed against the Epstein-Barr virus (EBV)-encoded nuclear
antigen 1 (EBNA1) detects MAGE-4: implications for studies on the EBV
association of human cancers. J Pathol 209: 430–435.
EBV and Breast Cancer
PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8180